ADCT Stock Analysis: Buy, Sell, or Hold?
ADCT - ADC Therapeutics SA
$1.05
-0.06 (-5.41%)
▼
5d:
-8.7%
30d:
-7.89%
90d:
-72.22%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When ADCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ADCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ADCT is currently trading at $1.05, which is considered oversold relative to its 30-day fair value range of $1.09 to $1.30.
Technical Outlook: Technically, ADCT is in a strong downtrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.00 (+376.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADCT is in a strong downtrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.00 (+376.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.09 -
$1.30
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 376.2% below Wall St target ($5.00)
- CAUTION: Recommendation downgraded due to -8.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.09 -
$1.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.05
Resistance Level
$1.40
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.58
Wall Street Target
$5.00
(+376.2%)
Revenue Growth (YoY)
-9.5%
Profit Margin
-173.0%
Share & Embed Analysis
Last updated: August 03, 2026 1:53 AM ET
Data refreshes hourly during market hours. Next update: 2:53 AM
Data refreshes hourly during market hours. Next update: 2:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Redmile Group, Llc
SELL
2529491 shares
2026-04-02
Redmile Group, Llc
SELL
2634506 shares
2026-04-02
Redmile Group, Llc
SELL
162517 shares
2026-04-01
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
